DOXOFYLLINE (SR) 400mg. IP + MONTELUKAST 10mg. IP

A combination medicine that is primarily used to treat and prevent asthma and chronic obstructive pulmonary diseases. Possesses both bronchodilating and anti-inflammatory activities. (Mario Cazzola, 2020) Significantly reduces exacerbations in patients with chronic mild to moderate asthma. (Hong Ping Zhang, 2014) Produces substantial improvements in symptoms and quality of life of patients with allergic rhinitis. (Zuzana Diamant, 2009) A safe and effective treatment for patients with both asthma and allergic rhinitis. (J Chr Virchow, 2006) Possesses a wider therapeutic window over conventional xanthines such as theophylline in the treatment of lung diseases. (Page, 2010) Provides an effective and well-tolerated treatment for allergic airway inflammation in patients with seasonal allergic rhinitis and perennial allergic rhinitis with/without asthma. (Anjuli Nayak, 2007) An effective and well-tolerated therapy in asthmatic patients. (Luigino Calzetta, 2020) An antibronchospastic drug that offers safe and effective treatment of obstructive lung disease. Provides a statistically significant reduction in the asthma attack rate. (Sami Manzoor Margay, 2015) A good alternative to theophylline in the treatment of reversible chronic airway obstruction. (G Melillo, 1989)